Multiple sclerosis in 2020: un bon cru
Résumé
Despite no major therapeutic trial results in 2020, the landscape of multiple sclerosis (MS) is changing, with better insight on prognosis, entry of artificial intelligence in MS brain imaging, technological advances challenging knowledge on disease pathogenesis, identification of novel therapeutic pathways. But 2020 will certainly be remembered as the year of outbreak
Domaines
Sciences du Vivant [q-bio]
Fichier principal
Maillart et Lubetzki - 2021 - Multiple sclerosis in 2020 un bon cru.pdf (563.52 Ko)
Télécharger le fichier
Origine : Fichiers produits par l'(les) auteur(s)